Literature DB >> 23885964

Factors associated with permanent hearing impairment in infants treated with therapeutic hypothermia.

Elisa Smit1, Xun Liu, Hannah Gill, Hemmen Sabir, Sally Jary, Marianne Thoresen.   

Abstract

OBJECTIVE: To define the incidence of hearing impairment, document plasma gentamicin concentrations, and identify factors associated with permanent hearing impairment in infants subjected to therapeutic hypothermia for moderate or severe neonatal encephalopathy. STUDY
DESIGN: Data were collected prospectively in a regional center providing therapeutic hypothermia. Cooled infants at ≥ 36 weeks gestation with moderate or severe neonatal encephalopathy were analyzed if a full dataset was available (n = 108), including clinical variables and gentamicin trough levels. Infants with hearing impairment were identified, and survivors were followed up with neurodevelopmental evaluation at age 18 months. Stepwise logistic regression identified factors associated with hearing impairment.
RESULTS: Nine infants died, and among the survivors, 10.1% developed a permanent hearing impairment. The trough gentamicin level was above the recommended cutoff of 2 mg/L in 37% of the infants in the entire cohort and in 90% of the infants with hearing impairment. Logistic regression analysis identified high trough gentamicin level, low cord pH, and hypoglycemia (<46.8 mg/dL) in the first postnatal hour as significantly associated with hearing impairment. The need for inotropic support was close to significant (P = .055).
CONCLUSION: Hearing impairment was a common finding among cooled infants. Plasma gentamicin levels were commonly >2 mg/L. Based on these findings, we propose changes in gentamicin dosing interval and trough level monitoring to minimize the risk of potentially toxic levels in cooled newborns.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  AABR; AOAE; Automated auditory brainstem response; Automated otoacoustic emissions; BSID-II; Bayley Scales of Infant Development, Second Edition; MDI; Mental Developmental Index; PDI; Pyschomotor Developmental Index

Mesh:

Substances:

Year:  2013        PMID: 23885964     DOI: 10.1016/j.jpeds.2013.06.012

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Bumetanide for neonatal seizures-back from the cotside.

Authors:  Ronit M Pressler; Geraldine B Boylan; Neil Marlow; Linda S de Vries; Mats Blennow; Catherine Chiron; J Helen Cross; Boubou Hallberg; Lena Hellström-Westas; Vincent Jullien; Barry Mangum; Brendan Murphy; Deirdre Murray; Gerard Pons; Janet Rennie; Mona C Toet; Sarah Zohar
Journal:  Nat Rev Neurol       Date:  2015-11-03       Impact factor: 42.937

Review 2.  Monitoring neonates for ototoxicity.

Authors:  Angela C Garinis; Alison Kemph; Anne Marie Tharpe; Joern-Hendrik Weitkamp; Cynthia McEvoy; Peter S Steyger
Journal:  Int J Audiol       Date:  2017-06-22       Impact factor: 2.117

3.  Clarifications regarding bumetanide for neonatal seizures.

Authors:  Kevin J Staley
Journal:  Epilepsia       Date:  2022-05-26       Impact factor: 6.740

4.  Epilepsy: Neonatal seizures still lack safe and effective treatment.

Authors:  Marianne Thoresen; Hemmen Sabir
Journal:  Nat Rev Neurol       Date:  2015-04-28       Impact factor: 42.937

5.  Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia.

Authors:  Yuma A Bijleveld; Timo R de Haan; Hanneke J H van der Lee; Floris Groenendaal; Peter H Dijk; Arno van Heijst; Rogier C J de Jonge; Koen P Dijkman; Henrica L M van Straaten; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Debbie H G M Nuytemans; Anton H van Kaam; Ron A A Mathot
Journal:  Br J Clin Pharmacol       Date:  2016-03-10       Impact factor: 4.335

6.  Pharmacokinetics of gentamicin in newborns with moderate-to-severe hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.

Authors:  Joseph Y Ting; Eddie Kwan; Al McDougal; Horacio Osiovich
Journal:  Indian J Pediatr       Date:  2014-07-29       Impact factor: 1.967

7.  Early and Late Onset Neonatal Sepsis: Epidemiology and Effectiveness of Empirical Antibacterial Therapy in a III Level Neonatal Intensive Care Unit.

Authors:  Marcello Mariani; Alessandro Parodi; Diego Minghetti; Luca A Ramenghi; Candida Palmero; Elisabetta Ugolotti; Chiara Medici; Carolina Saffioti; Elio Castagnola
Journal:  Antibiotics (Basel)       Date:  2022-02-21

Review 8.  The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis.

Authors:  Yehezkel Ben-Ari; Enrico Cherubini
Journal:  Cells       Date:  2022-01-24       Impact factor: 6.600

9.  A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders.

Authors:  Eric Delpire; Yehezkel Ben-Ari
Journal:  Cells       Date:  2022-08-04       Impact factor: 7.666

10.  A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.

Authors:  Janet S Soul; Ann M Bergin; Christian Stopp; Breda Hayes; Avantika Singh; Carmen R Fortuno; Deirdre O'Reilly; Kalpathy Krishnamoorthy; Frances E Jensen; Valerie Rofeberg; Min Dong; Alexander A Vinks; David Wypij; Kevin J Staley
Journal:  Ann Neurol       Date:  2020-12-03       Impact factor: 10.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.